A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients With Acute Decompensated Alcoholic Hepatitis
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Epeleuton (Primary)
- Indications Alcoholic hepatitis
- Focus Therapeutic Use
- Sponsors Afimmune
- 05 Dec 2019 This trial has been discontinued in Germany, according to European Clinical Trials Database record.
- 12 Nov 2018 Planned initiation date changed from 1 Jun 2018 to 1 Nov 2018.
- 26 Feb 2018 Status changed from planning to not yet recruiting.